A banner from Moderna's 2023 campaign to highlight the power of mRNA to transform medicine. In January, Moderna was celebrating a $590 million contract with the US government to develop pandemic flu ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its contender for the United States’ first mRNA-based ...

FDA's advisory committee will vote on June 18 whether mFlusiva benefits outweigh risks in older adults Moderna seeks accelerated approval of mFlusiva for adults 65 and older If approved, mFlusiva will ...

June 16 (Reuters) - Staff of the U.S. Food and Drug Administration said on Tuesday that data demonstrating a strong immune ‌response to Moderna's flu shot may support effectiveness in adults 65 years ...

Moderna (MRNA) on Tuesday said that Ester Banque, a former senior executive at Zoetis (ZTS) and Bristol Myers (BMY), will join the company as chief commercial officer as part of organizational changes ...

Moderna (MRNA) shares reached the highest level since March after the FDA issued comments that Jefferies said gave a “balanced” view on the company’s flu vaccine candidate, mRNA-1010, ahead of an ...

Moderna is restructuring its organization and leadership in preparation for a new wave of product launches, expanding President Stephen Hoge's role and appointing longtime pharma executive Ester ...

June 16 (Reuters) - Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises, the vaccine maker said on Tuesday, as it prepares for potential ...

S&P 500 ends lower; chips tumble and Moderna rallies The S&P 500 ended marginally lower on Friday, with a steep drop in AI-related chip stocks and sharp gains in Moderna and other healthcare stocks.